Cardiovascular Biomarkers and Calculated Cardiovascular Risk in Orally Treated Type 2 Diabetes Patients: Is There a Link?

摘要: The aim of the study was to test correlation serum levels of asymmetric dimethylarginine (ADMA), endothelin 1 (ET-1), N-terminal brain natriuretic pro-peptide (NT-proBNP), and placental growth factor (PIGF-1) with estimated cardiovascular (CV) risk. group composed 102 women 67 men type 2 diabetes, having their glycemic metabolic parameters assessed. All were on oral antidiabetic drugs. Serum NT-proBNP PIGF-1 measured by electro-hemi-luminescence an Elecsys 2010 analyzer. Enzymatic immunoassays used for ADMA ET-1. Framingham Risk Score (FRS), UKPDS 2.0 ADVANCE risk engines calculate risks while statistical analysis was performed SPSS. Levels showed no the calculated CV risks. same true ADMA, except a weak UKPDS-based 10-year stroke (Pearsons’s R=0.167, p=0.039). Plasma ET-1 correlated (R=0.184, p=0.032) fatal (R=0.215, p=0.012) only. significantly correlated all calculations: ADVANCE-based 4-yr (Spearman’s Rho=0.521, p<0.001); for: CHD (Rho=0.209, p=0.01), (Rho=0.282, p<0.001), stroke (Rho=0.482, (Rho=0.505, FRS (Rho=0.246, p=0.002). In conclusion, did not seem useful in stratifying risk is linked stroke, estimations.